Christos Papadimitriou
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Year:
2026
Gene expression across responses categories and treatments. Dots represent outliers. CR, complete response; NE, non-evaluable; PR, partial response; PD, progressive disease; SD, stable disease.
Year:
2024
Gene expression across responses categories and treatments. Dots represent outliers. CR, complete response; NE, non-evaluable; PR, partial response; PD, progressive disease; SD, stable disease.
Year:
2024
Purpose: Suboptimal treatment outcomes with 5-fluorouracil (5-FU)/folate, the standard of care for metastatic colorectal cancer (mCRC), have generated interest in optimizing the folate. Arfolitixorin ([6R]-5,10-methylene-tetrahydrofolate) is an immediately active folate and may improve outcomes over the existing standard of care (leucovorin). Experimental Design: AGENT was a randomized, phase III study (NCT03750786). Patients with mCRC were randomized to arfolitixorin (120 mg/m 2 given as two intravenous bolus doses of 60 mg/m 2 ) or leucovorin (400 mg/m 2 given as a single intravenous infusion) plus 5-FU, oxaliplatin, and bevacizumab. Assessments were performed every 8 weeks. The primary endpoint was the superiority of arfolitixorin for overall response rate (ORR). Results: Between February 2019 and April 2021, 490 patients were randomized (245 to each arm). After a median follow-up of 266 days, the primary endpoint of superiority for ORR was not achieved (48.2% for arfolitixorin vs. 49.4% for leucovorin, P superiority = 0.57). Outcomes were not achieved for median progression-free survival (PFS; 12.8 and 11.6 months, P = 0.38), median duration of response (12.2 and 12.9 months, P = 0.40), and median overall survival (23.8 and 28.0 months, P = 0.78). The proportion of patients with an adverse event of grade ≥3 severity was similar between arms (68.7% and 67.2%, respectively), as was quality of life. BRAF mutations and MTHFD2 expression were both associated with a lower PFS with arfolitixorin. Conclusions: The study failed to demonstrate clinical benefit of arfolitixorin (120 mg/m 2 ) over leucovorin. However, it provides some useful insights from the first-line treatment setting, including the effect of gene expression on outcomes. Significance: This phase III study compared arfolitixorin, a direct-acting folate, with leucovorin in FOLFOX plus bevacizumab in mCRC. Arfolitixorin (120 mg/m 2 ) did not improve the ORR, potentially indicating a suboptimal dose.
Year:
2024
Purpose: Suboptimal treatment outcomes with 5-fluorouracil (5-FU)/folate, the standard of care for metastatic colorectal cancer (mCRC), have generated interest in optimizing the folate. Arfolitixorin ([6R]-5,10-methylene-tetrahydrofolate) is an immediately active folate and may improve outcomes over the existing standard of care (leucovorin). Experimental Design: AGENT was a randomized, phase III study (NCT03750786). Patients with mCRC were randomized to arfolitixorin (120 mg/m 2 given as two intravenous bolus doses of 60 mg/m 2 ) or leucovorin (400 mg/m 2 given as a single intravenous infusion) plus 5-FU, oxaliplatin, and bevacizumab. Assessments were performed every 8 weeks. The primary endpoint was the superiority of arfolitixorin for overall response rate (ORR). Results: Between February 2019 and April 2021, 490 patients were randomized (245 to each arm). After a median follow-up of 266 days, the primary endpoint of superiority for ORR was not achieved (48.2% for arfolitixorin vs. 49.4% for leucovorin, P superiority = 0.57). Outcomes were not achieved for median progression-free survival (PFS; 12.8 and 11.6 months, P = 0.38), median duration of response (12.2 and 12.9 months, P = 0.40), and median overall survival (23.8 and 28.0 months, P = 0.78). The proportion of patients with an adverse event of grade ≥3 severity was similar between arms (68.7% and 67.2%, respectively), as was quality of life. BRAF mutations and MTHFD2 expression were both associated with a lower PFS with arfolitixorin. Conclusions: The study failed to demonstrate clinical benefit of arfolitixorin (120 mg/m 2 ) over leucovorin. However, it provides some useful insights from the first-line treatment setting, including the effect of gene expression on outcomes. Significance: This phase III study compared arfolitixorin, a direct-acting folate, with leucovorin in FOLFOX plus bevacizumab in mCRC. Arfolitixorin (120 mg/m 2 ) did not improve the ORR, potentially indicating a suboptimal dose.
Year:
2024
Neoadjuvant chemotherapy (NACT) for certain breast cancer (BC) subtypes confers significant tumor regression rates and a survival benefit for patients with a complete pathologic response. Clinical and preclinical studies have demonstrated that immune-related factors are responsible for better treatment outcomes, and thus, neoadjuvant immunotherapy (IO) has emerged as a means to further improve patient survival rates. Innate immunological “coldness”, however, of specific BC subtypes, especially of the luminal ones, due to their immunosuppressive tumor microenvironment, hinders the efficacy of immune checkpoint inhibitors. Treatment policies aiming to reverse this immunological inertia are, therefore, needed. Moreover, radiotherapy (RT) has been proven to have a significant interplay with the immune system and promote anti-tumor immunity. This “radiovaccination” effect could be exploited in the neoadjuvant setting of BC and significantly enhance the effects of the already established clinical practice. Modern stereotactic irradiation techniques directed to the primary tumor and involved lymph nodes may prove important for the RT-NACT-IO combination. In this review, we provide an overview and critically discuss the biological rationale, clinical experience, and ongoing research underlying the interplay between neoadjuvant chemotherapy, anti-tumor immune response, and the emerging role of RT as a preoperative adjunct with immunological therapeutic implications in BC.
Year:
2023
Collaborators (6)
Nikos Vlahos
Professor and chairman
National and Kapodistrian University of Athens
Roger Tell
Chief Medical Officer
-
Heinz-Josef Lenz
University of Southern California
Gerald W. Prager
Medical University of Vienna
Sebastian Stintzing
Professor
Charité - Universitätsmedizin Berlin
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Make your next move.
Prepare your application
Review drafts before you send them.